Absci Corporation Common Stock (ABSI) Stock Price

ABSIStock

$9.63+236.12%52W

Market Cap$1.65B

P/E—

PEG Ratio—

Div yield—

Beta2.28

ABSI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)216.16%

Price vs S&P 500 (4W)20.93%

VGM Score34.14

Book Value / Share (Quarterly)$1.11

P/TBV (Annual)3.55x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-21.33%

Cash Flow / Share (Quarterly)$-0.63

Price vs S&P 500 (YTD)141.34%

Net Profit Margin (TTM)-6450.76%

EPS (TTM)$-0.83

10-Day Avg Trading Volume2.83M

EPS Excl Extra (TTM)$-0.83

Revenue Growth (5Y)-10.14%

EPS (Annual)$-0.84

ROI (Annual)-60.52%

Net Profit Margin (5Y Avg)-2451.57%

Cash / Share (Quarterly)$0.81

Revenue Growth QoQ (YoY)-81.76%

ROA (Last FY)-53.25%

Revenue Growth TTM (YoY)-61.87%

EBITD / Share (TTM)$-0.78

ROE (5Y Avg)-49.39%

Operating Margin (TTM)-6722.98%

Cash Flow / Share (Annual)$-0.62

P/B Ratio9.44x

P/B Ratio (Quarterly)2.71x

Net Income / Employee (Annual)$-822,700

EV / Revenue (TTM)879.77x

Net Interest Coverage (TTM)-549.78x

ROA (TTM)-54.66%

EPS Incl Extra (Annual)$-0.84

Current Ratio (Annual)6.57x

Quick Ratio (Quarterly)6.28x

3-Month Avg Trading Volume5.07M

52-Week Price Return236.12%

Revenue / Employee (TTM)$13,100

Tangible BV / Share (Quarterly)$0.84

P/S Ratio (Annual)579.81x

Asset Turnover (Annual)0.01x

52-Week High$12.05

Operating Margin (5Y Avg)-2431.34%

EPS Excl Extra (Annual)$-0.84

CapEx CAGR (5Y)-12.68%

26-Week Price Return227.41%

Quick Ratio (Annual)6.34x

13-Week Price Return73.67%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.59x

Enterprise Value$1.62B

Revenue / Share Growth (5Y)-17.27%

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$20,000

Pretax Margin (Annual)-4111.21%

Cash / Share (Annual)$0.95

3-Month Return Std Dev126.30%

Net Income / Employee (TTM)$-846,000

ROE (Last FY)-60.80%

Net Interest Coverage (Annual)-798.63x

EPS Basic Excl Extra (Annual)$-0.84

Receivables Turnover (TTM)13.74x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.83

Receivables Turnover (Annual)3.86x

ROI (TTM)-63.17%

P/S Ratio (TTM)884.24x

Pretax Margin (5Y Avg)-2489.30%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.98

Price vs S&P 500 (52W)217.81%

Year-to-Date Return153.30%

5-Day Price Return-0.11%

EPS Normalized (Annual)$-0.84

ROA (5Y Avg)-41.75%

Net Profit Margin (Annual)-4113.68%

Month-to-Date Return13.62%

Cash Flow / Share (TTM)$-1.01

EBITD / Share (Annual)$-0.79

Operating Margin (Annual)-4297.04%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-47.98%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.83

P/TBV (Quarterly)3.55x

P/B Ratio (Annual)2.77x

Pretax Margin (TTM)-6445.81%

Book Value / Share (Annual)$1.25

Price vs S&P 500 (13W)70.88%

Beta2.28x

Revenue / Share (TTM)$0.01

ROE (TTM)-63.58%

52-Week Low$2.24

vGradeF

gGradeF

mGradeA

vgmGradeD

ABSI Earnings Surprise History

Q2 25-0.24est. -0.21

Q3 25-0.20est. -0.22

Q4 25-0.23est. -0.17

Q1 26-0.19est. -0.20

Q2 26-0.21est. -0.20

ABSI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.07

4.13

4.18

4.13

Industry Peers — R&D — Physical Sciences(16)

Symbol	Value Score	Growth Score	Momentum Score	Price
ABSIAbsci Corporation Common Stock	F	F	A	$9.63
IQVIQVIA Holdings Inc.	D	C	A	$259.42
INCYIncyte Genomics Inc	C	A	B	$129.72
MEDPMedpace Holdings, Inc. Common Stock	F	B	A	$614.06
CRLCharles River Laboratories International, Inc.	D	D	A	$297.64
ICLRIcon Plc	C	C	B	$168.91
OABIOmniAb, Inc. Common Stock	D	C	A	$4.66
NRCNRC Health Common Stock	D	D	B	$22.02
MXCTMaxCyte, Inc. Common Stock	C	D	B	$1.35
IBACIB Acquisition Corp. Common Stock	—	D	C	$10.89
ONMDOneMedNet Corp Class A Common Stock	D	C	D	$0.59
ISPCiSpecimen Inc. Common Stock	D	F	F	$1.60
BIAFbioAffinity Technologies, Inc. Common Stock	A	F	F	$5.19
BIAFWbioAffinity Technologies, Inc. Warrant	—	—	C	$0.08
NOTVInotiv, Inc. Common Stock	A	B	F	$0.01
OABIWOmniAb, Inc. Warrant	—	—	B	$0.23
ONMDWOneMedNet Corp Warrant	—	—	F	$0.03

About Absci Corporation Common Stock

Absci Corp is an AI-powered synthetic biology company focused on developing novel protein therapeutics. Its integrated platform unifies biologic drug discovery and cell line development, enabling faster creation of next-generation biologics.